[1]
|
Jorm, A.F., Korten, A.E. and Henderson, A.S. (1987) The Prevalence of Dementia: A Quantitative Integration of the Literature. Acta Psychiatrica Scandinavica, 76, 465-479. http://dx.doi.org/10.1111/j.1600-0447.1987.tb02906.x
|
[2]
|
Brookmeyer, R., Gray, S. and Kawas, C. (1998) Projections of Alzheimer’s Disease in the Unites States and the Public Health Impact of Delaying Disease Onset. American Journal of Public Health, 88, 1337-1342. http://dx.doi.org/10.2105/AJPH.88.9.1337
|
[3]
|
Hussain, I., Powell, D.J., Howlett, D.R., Tew, D.G., Meek, T.D., Chapman, C., et al. (1999) Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase. Molecular and Cellular Neuroscience, 14, 419-427. http://dx.doi.org/10.1006/mcne.1999.0811
|
[4]
|
Sinha, S., Anderson, J.P., Barbour, R., Basi, G.S., Caccavello, R., Davis, D., et al. (1999) Purification and Cloning of Amyloid Precursor Protein Beta-Secretase from Human Brain. Nature, 402 , 537-540. http://dx.doi.org/10.1038/990114
|
[5]
|
Vassar, R., Bennett, B.D., Babu-Khan, S., Khan, S., Mendiaz, E.A., Denis, P., et al. (1999) Beta-Secretase Cleavage of Alzheimer’s Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE. Science, 286, 735-741. http://dx.doi.org/10.1126/science.286.5440.735
|
[6]
|
Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C., et al. (1999) Membrane-Anchored Aspartyl Protease with Alzheimer’s Disease Beta-Secretase Activity. Nature, 402, 533-537. http://dx.doi.org/10.1038/990107
|
[7]
|
Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A. and Tang, J. (2000) Human Aspartic Protease Memapsin 2 Cleaves the Beta-Secretase Site of Beta-Amyloid Precursor Protein. Proceedings of the National Academy of Sciences of the United States of America, 97, 1456-1460. http://dx.doi.org/10.1073/pnas.97.4.1456
|
[8]
|
Vassar, R. (2002) Beta-Secretase (BACE) as a Drug Target for Alzheimer’s Disease. Advanced Drug Delivery Reviews, 54, 1589-1602. http://dx.doi.org/10.1016/S0169-409X(02)00157-6
|
[9]
|
Cole, S.L. and Vassar, R. (2007) The Alzheimer’s Disease Beta-Secretase Enzyme, BACE1. Molecular Neurodegeneration, 2, 22. http://dx.doi.org/10.1186/1750-1326-2-22
|
[10]
|
Selkoe, D.J. (1991) The Molecular Pathology of Alzheimer’s Disease. Neuron, 6, 487-498. http://dx.doi.org/10.1016/0896-6273(91)90052-2
|
[11]
|
Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356. http://dx.doi.org/10.1126/science.1072994
|
[12]
|
Deane, R. and Zlokovic, B.V. (2007) Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimer’s Disease. Current Alzheimer Research, 4, 191-197. http://dx.doi.org/10.2174/156720507780362245
|
[13]
|
Lasierra-Cirujeda, J., Coronel, P., Aza, M.J. and Gimeno, M. (2013) Beta-Amyloidolysis and Glutathione in Alzheimer’s Disease. Journal of Blood Medicine, 4, 31-38. http://dx.doi.org/10.2147/JBM.S35496
|
[14]
|
Saido, T. and Leissring, M.A. (2012) Proteolytic Degradation of Amyloid β-Protein. Cold Spring Harbor Perspectives in Medicine, 2, a006379. http://dx.doi.org/10.1101/cshperspect.a006379
|
[15]
|
Howell, S., Nalbantoglu, J. and Crine, P. (1995) Neutral Endopeptidase Can Hydrolyze Beta-Amyloid(1-40) but Shows No Effect on Beta-Amyloid Precursor Protein Metabolism. Peptides, 16, 647-652. http://dx.doi.org/10.1016/0196-9781(95)00021-B
|
[16]
|
Takaki, Y., Iwata, N., Tsubuki, S., Taniguchi, S., Toyoshima, S., Lu, B., et al. (2000) Biochemical Identification of the Neutral Endopeptidase Family Member Responsible for the Catabolism of Amyloid Beta-Peptide in the Brain. The Journal of Biochemistry, 128, 897-902. http://dx.doi.org/10.1093/oxfordjournals.jbchem.a022839
|
[17]
|
Iwata, N., Tesubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., et al. (2001) Metabolic Regulation of Brain Abeta by Neprilysin. Science, 292, 1550-1552. http://dx.doi.org/10.1126/science.1059946
|
[18]
|
Shirotani, K., Tsubuki, S, lwata, N., Takaki, Y., Harigaya, W., Matuyama, K., et al. (2001) Neprilysin Degrades both Amyloid Beta Peptides 1-40 and 1-42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-Sensitive Endopeptidases. The Journal of Biochemistry, 276, 21895-21901. http://dx.doi.org/10.1074/jbc.M008511200
|
[19]
|
Leissring, M.A., Farris, W., Chang, A.Y., Walsh, D.M., Wu, X., Sun, X., et al. (2003) Enhanced Proteolysis of Beta-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death. Neuron, 40, 1087-1093.
|
[20]
|
Marr, R.A., Rockenstein, E., Mukherjee, A., Kindy, M.S., Hersh, L.B., Gage, F.H., et al. (2003) Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice. The Journal of Neuroscience, 23, 1992-1996.
|
[21]
|
Caccamo, A., Oddo, S., Sugarman, M.C., Akbari, Y. and LaFerla, F.M. (2005) Age and Region-Dependent Alterations in Abeta-Degrading Enzymes: Implications for Abeta-Induced Disorders. Neurobiology of Aging, 26, 645-654. http://dx.doi.org/10.1016/j.neurobiolaging.2004.06.013
|
[22]
|
Eckeman, E.A. and Eekeman, C.B. (2005) Abeta-Degrading Enzymes: Modulators of Alzheimer’s Disease Pathogenesis and Targets for Therapeutic Intervention. Biochemical Society Transactions, 33, 1101-1105.
|
[23]
|
Eckman, E.A., Adams, S.K., Troendle, F.J., Stodola, A., Kanh, M.A., Faugh, A.H., et al. (2006) Regulation of Steady-State Beta-Amyloid Levels in the Brain by Neprilysin and Endothelin-Convertig Enzyme but Not Angiotensin-Convertin Enzyme. The Journal of Biological Chemistry, 281, 30471-30478. http://dx.doi.org/10.1074/jbc.M605827200
|
[24]
|
Hersh, L.B. and Rodgers, D.W. (2008) Neprilysin and Amyloid Beta Peptide Degradation. Current Alzheimer Research, 5, 225-231. http://dx.doi.org/10.2174/156720508783954703
|
[25]
|
Wang, S., Wang, R., Chen, L., Bennett, D.A., Dickson, D.W. and Wang, D.S. (2010) Expression and Functional Profiling of Neprilysin, Insulin Degrading Enzyme and Endothelin Converting Enzyme in Prospectively Studied Elderly and Alzheimer’s Brain. Journal of Neurochemistry, 115, 47-57. http://dx.doi.org/10.1111/j.1471-4159.2010.06899.x
|
[26]
|
Authier, F., Posner, B.I. and Bergeron, J.J. (1996) Insulin-Degrading Enzyme. Clinical & Investigative Medicine, 19, 149-160.
|
[27]
|
de Tullio, M.B., Morelli, L. and Castano, E.M. (2008) The Irreversible Binding of Amyloid Peptide Substrates to Insulin-Degrading Enzyme: A Biological Perspective. Prion, 2, 51-56. http://dx.doi.org/10.4161/pri.2.2.6710
|
[28]
|
Kingston, I.B., Castro, M.J. and Anderson, S. (1995) In Vitro Stimulation of Tissue-Type Plasminogen Activator by Alzheimer Amyloid Beta-Peptide Analogues. Nature Medicine, 1, 138-142. http://dx.doi.org/10.1038/nm0295-138
|
[29]
|
Wnendt, S., Wetzels, I. and Gúnzler, W.A. (1997) Amyloid Beta Peptides Stimulate Tissue-Type Plasminogen Activator but Not Recombinant Prourokinase. Thrombosis Research, 85, 217-224. http://dx.doi.org/10.1016/S0049-3848(97)00006-6
|
[30]
|
Van Nostrand, W.E. and Porter, M. (1999) Plasmin Cleavage of the Amyloid Beta-Protein: Alteration of Secondary Structure and Stimulation of Tissue Plasminogen Activator Activity. Biochemistry, 38, 11570-11576. http://dx.doi.org/10.1021/bi990610f
|
[31]
|
Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi, T., Price, D., et al. (2000) The Plasmin System Is Induced by and Degrades Amyloid-Beta Aggregates. The Journal of Neuroscience, 20, 3937-3946.
|
[32]
|
Melchor, J.P., Pawlak, R. and Strickland, S. (2003) The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-Beta (Abeta) Degradation and Inhibits Abeta-Induced Neurodegeneration. The Journal of Neuroscience, 23, 8867-8871.
|
[33]
|
Jacobsen, J.S., Comely, T.A., Martone, R.L., Elokdah, H., Crandall, D.L., Oganesian, A., et al. (2008) Enhanced Clearance of Aβ in Brain by Sustaining the Plasmin Proteolysis Cascade. Proceedings of the National Academy of Sciences of the United States of America, 105, 8754-8759. http://dx.doi.org/10.1073/pnas.0710823105
|
[34]
|
Mukherjee, A. and Hersh, L.B. (2002) Regulation of Amyloid Beta-Peptide Levels by Enzymatic Degradation. Journal of Alzheimer’s Disease, 4, 341-348.
|
[35]
|
Strickland, S. (2001) Tissue Plasminogen Activator in Nervous System Function and Dysfunction. Thrombosis and Haemostasis, 86, 138-143.
|
[36]
|
Kranenburg, O., Gent, Y.Y., Romijn, E.P., Voest, E.E., Heck, A.J. and Gebbink, M.F. (2005) Amyloid-Beta-Stimu- lated Plasminogen Activation by Tissue-Type Plasminogen Activator Results in Processing of Neuroendocrine Factors. Neuroscience, 131, 877-886. http://dx.doi.org/10.1016/j.neuroscience.2004.11.044
|
[37]
|
Miners, J.S., Barua, N., Kehoe, P.G., Gill, S. and Love, S. (2011) Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. Journal of Neuropathology & Experimental Neurology, 70, 944-959. http://dx.doi.org/10.1097/NEN.0b013e3182345e46
|
[38]
|
Nalivaeva, N.N., Fisk, L.R., Belyaev, N.D. and Turner, A.J. (2008) Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimer’s Disease. Current Alzheimer Research, 5, 212-224. http://dx.doi.org/10.2174/156720508783954785
|
[39]
|
de Strooper, B. (2010) Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. Physiological Reviews, 90, 465-494. http://dx.doi.org/10.1152/physrev.00023.2009
|
[40]
|
Leal, M.C., Fernandez, A., Morelli, L. and Castano, E.M. (2009) Cerebral Proteolysis of Amyloid-β Peptide: Relevance of Insulin-Degrading Enzyme in Alzheimer’s Disease. Medicina (B Aires), 69, 466-472.
|
[41]
|
Lasierra-Cirujeda, J., Coronel, P., Aza, M.J. and Gimeno, M. (2010) Use of Sulodexide in Patiens with Peripheral Vascular Disease. Journal of Blood Medicine, 1, 105-115. http://dx.doi.org/10.2147/JBM.S10558
|
[42]
|
Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) Mini-Mental State: A Practical Method for Grading the Cognitive State of Patients for the Clinician. Journal of Psychiatric Research, 12, 189-198. http://dx.doi.org/10.1016/0022-3956(75)90026-6
|
[43]
|
Robles, A., Del Ser, T., Alom, J. and Pefia-Casanova, J. (2002) Propuesta de criterios para el diagnóstico del deterioro cognitivo ligero, la demencia y la enfermedad de Alzheimer. Neurología, 17, 17-32.
|
[44]
|
Tapia Granados, J.A. (1994) Incidencia: Concepto, terminología y análisis dimensional. Medicina Clínica, 103, 140-142.
|
[45]
|
Engbers, M.J., van Hylckama Vlieg, A. and Rosendaal, F.R. (2010) Venous Thrombosis in the Elderly: Incidence, Risk Factors and Risk Group. Journal of Thrombosis and Haemostasis, 8, 2105-2112. http://dx.doi.org/10.1111/j.1538-7836.2010.03986.x
|
[46]
|
Yamamoto, K., Takeshita, K., Kojima, T., Takamatsu, J. and Saito, H. (2005) Aging and Plasminogen Activator Inhibitor-1 (PAI-1) Regulation: Implication in the Pathogenesis of Thrombotic Disorders in the Elderly. Cardiovascular Research, 66, 276-285. http://dx.doi.org/10.1016/j.cardiores.2004.11.013
|
[47]
|
Tofler, G.H., Massaro, J., Levy, D., Mittleman, M., Sutherland, P., Lipinska, I., et al. (2005) Relation of the Prothrombotic State to Increasing Age (from the Framinghan Offspring Study). American Journal of Cardiology, 96, 1280-1283. http://dx.doi.org/10.1016/j.amjcard.2005.06.072
|
[48]
|
Lew, S.J. and Lim, J.K. (2002) Stroke Prevention in Elderly Patients with Atrial Fibrillation. Singapore Medical Journal, 43, 198-201.
|
[49]
|
Zellerhoff, S., Goette, A. and Kirchhof, P. (2006) Anticoagulation with Atrial Fibrillation. Herzschrittmachertherapie & Elektrophysiologie, 17, 89-94. http://dx.doi.org/10.1007/s00399-006-0515-z
|
[50]
|
Dhond, A.J., Michelena, H.I. and Ezekowitz, M.D. (2003) Anticoagulation in the Elderly. The American Journal of Geriatric Cardiology, 12, 243-250. http://dx.doi.org/10.1111/j.1076-7460.2003.02010.x
|
[51]
|
Robert-Ebadi, H., Le Gal, G. and Righini, M. (2009) Use of Anticoagulants in Elderly Patients: Practical Recommendations. Clinical Interventions in Aging, 4, 165-177.
|
[52]
|
Loskutoff, D.J., Sawdey, M. and Mimuro, J. (1988) Type 1 Plasminogen Activator Inhibitor. In: Coller, B., Ed., Progress in Hemostasis and Thrombosis, WB Saunders, Philadelphia, 87-115.
|
[53]
|
Yamamoto, K., Takeshita, K., Shimokawa, T., Yi, H., Isobe, K., Loskutof, D.J., et al. (2002) Plasminogen Activator Inhibitor-1 Is a Major Stress-Regulated Gene: Implications for Stress-Induced Thrombosis in Aged Individuals. Proceedings of the National Academy of Sciences of the United States of America, 99, 890-895. http://dx.doi.org/10.1073/pnas.022608799
|
[54]
|
Naderali, E.K., Ratcliffe, S.H. and Dale, M.C. (2009) Review: Obesity and Alzheimer’s Disease: A Link between Body Weight and Cognitive Function in Old Aged. American Journal of Alzheimer’s Disease & Other Dementias, 24, 445-449. http://dx.doi.org/10.1177/1533317509348208
|
[55]
|
Hashimoto, Y., Kobayashi, A., Yamazaki, N., Sugawara, Y., Takada, Y. and Takada, A. (1987) Relationship between Age and Plasma t-PA, PA-Inhibitor, and PA Activity. Thrombosis Research, 46, 625-633. http://dx.doi.org/10.1016/0049-3848(87)90264-7
|
[56]
|
Aoyama, K. and Nakaki, T. (2013) Impaired Glutathione Synthesis in Neurodegeneration. International Journal of Molecular Sciences, 14, 21021-21044. http://dx.doi.org/10.3390/ijms141021021
|
[57]
|
Gu, F., Chauhan, V. and Chauhan, A. (2015) Glutathione Redox Imbalance in Brain Disorders. Current Opinion in Clinical Nutrition & Metabolic Care, 18, 89-95. http://dx.doi.org/10.1097/MCO.0000000000000134
|
[58]
|
Cirujeda, J.L. and Granado, P.C. (2006) A Study on the Safety, Efficacy, and Efficiency of Sulodexide Compared with Acenocoumarol in Secondary Prophylaxis in Patients with Deep Venous Thrombosis. Angiology, 57, 53-64. http://dx.doi.org/10.1177/000331970605700108
|
[59]
|
Marín, F., Roldan, V., Marco, P., Martinez, J.G., Toral, A., García de Burgos, F., et al. (1999) Improvement in Fibrinolytic Function Following Anticoagulant Treatment in Chronic Rheumatic Atrial Fibrillation. Revista Espanola de Cardiología, 52, 25-30.
|
[60]
|
Roldán, V., Marin, F., Marco, P., Climent, V., Martinez, J.G., Monmeneu, J.V., et al. (2000) Anticoagulant Therapy Modifies Fibrinolytic Dysfuntion in Chronic Atrial Fibrilation. Haemostasis, 30, 219-224.
|
[61]
|
van Deelen, B. A., van den Bemt, P.M., Egberts, T.C., van’t Hoff, A. and Maas, H.A. (2005) Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulant Treatment in Elderly Patients with Atrial Fibrillation. Drugs & Aging, 22, 353-360. http://dx.doi.org/10.2165/00002512-200522040-00007
|
[62]
|
Flaker, G.C., Pogue, J., Yusuf, S., Pfeffer, M. A., Goldhaber, S. Z., Granger, C.B., et al. (2010) Cognitive Function and Anticoagulation Control in Patients with Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 3, 277-283. http://dx.doi.org/10.1161/CIRCOUTCOMES.109.884171
|
[63]
|
Jacobs, L.G., Billett, H.H., Freeman, K., Dinglas, C. and Jumaquio, L. (2009) Anticoagulation for Stroke Prevention in Elderly Patients with Atrial Fibrillation, Including Those with Falls and/or Early-Stage Dementia: A Single-Center, Retrospective, Observational Study. The American Journal of Geriatric Pharmacotherapy, 7, 159-166. http://dx.doi.org/10.1016/j.amjopharm.2009.06.002
|
[64]
|
Singer, D.E., Fang, M.C. and Go, A.S. (2009) The International Normalized Ratio Range of 2.0 to 3.0 Remains Appropriate for Atrial Fibrillation. Archives of Internal Medicine, 169, 2032. http://dx.doi.org/10.1001/archinternmed.2009.419
|
[65]
|
Luchsinger, J.A. and Mayeux, R. (2004) Cardiovascular Risk Factors and Alzheimer’s Disease. Current Atherosclerosis Reports, 6, 261-266. http://dx.doi.org/10.1007/s11883-004-0056-z
|
[66]
|
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R.C., Ritchie, K., Broich, K., et al. (2006) Mild Cognitive Impairment. The Lancet, 367, 1262-1270. http://dx.doi.org/10.1016/S0140-6736(06)68542-5
|
[67]
|
Jicha, G.A., Parisi, J.E., Dickson, D.W., Johnson, K., Cha, R., Ivnik, R.J., et al. (2006) Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 63, 674-681. http://dx.doi.org/10.1001/archneur.63.5.674
|
[68]
|
Kivipelto, M., Helkala, E.L., Laakso, M.P., Hanninen, T., Hallikainen, M., Alhainen, K., et al. (2001) Midlife Vascular Risk Factors and Alzheimer’s Disease in Later Life: Longitudinal, Population Based Study. British Medical Journal, 322, 1447-1451. http://dx.doi.org/10.1136/bmj.322.7300.1447
|
[69]
|
Weissmann, P., Consalvo, D., Solis, P., Baglivo, H., Ramirez, A. and Sanchez, R. (2002) Hipertension arterial y deterioro cognitivo en el anciano. Revista Argentina de Cardiologia, 70, 231-238.
|
[70]
|
Skoog, I. and Gustafson, D. (2003) Hypertension, Hypertension-Clustering Factors and Alzheimer’s Disease. Neurological Research, 25, 675-680. http://dx.doi.org/10.1179/016164103101201986
|
[71]
|
Staessen, J.A. and Birkenhager, W.H. (2004) Cognitive Impairment and Blood Pressure. Hypertension, 44, 612-613. http://dx.doi.org/10.1161/01.HYP.0000145864.95630.20
|
[72]
|
Anson, O. and Paran, E. (2005) Hypertension and Cognitive Functioning among the Elderly: An Overview. American Journal of Therapeutics, 12, 359-365. http://dx.doi.org/10.1097/01.mjt.00001= 09849.55405.48
|
[73]
|
Skoog, I. and Gustafson, D. (2006) Update on Hypertension and Alzheimer’s Disease. Neurological Research, 28, 605-611. http://dx.doi.org/10.1179/016164106X130506
|
[74]
|
Staessen, J.A., Richart, T. and Birkenhager, W.H. (2007) Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective with More Brain. Hypertension, 49, 389-400. http://dx.doi.org/10.1161/01.HYP.0000258151.00728.d8
|
[75]
|
Elias, M.F. and Dore, G.A. (2008) Brain Indices Predict Blood Pressure Control: Aging Brains and New Predictions. Hypertension, 52, 1014-1015. http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.122713
|
[76]
|
Elias, M.F., Elias, P.K., Dore, G.A. and Robbins, M.A. (2008) High-Normal Blood Pressure and Cognition: Supplying the Missing Data. Hypertension, 52, e1-e2. http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.114165
|
[77]
|
Birns, J. and Kalra, L. (2009) Cognitive Function and Hypertension. Journal of Human Hypertension, 23, 86-96. http://dx.doi.org/10.1038/jhh.2008.80
|
[78]
|
Hofman, A., Ott, A., Breteler, M.M., Bots, M.L., Slooter, A.J., van Harskamp, F., et al. (1997) Atherosclerosis, Apolipoprotein E, and Prevalence of Dementia and Alzheimer’s Disease in the Rotterdam Study. The Lancet, 349, 151-154. http://dx.doi.org/10.1016/S0140-6736(96)09328-2
|
[79]
|
Casserly, I. and Topol, E. (2004) Convergence of Atherosclerosis and Alzheimer ’s Disease: Inflammation, Cholesterol, and Misfolded Proteins. The Lancet, 363, 1139-1146. http://dx.doi.org/10.1016/S0140-6736(04)15900-X
|
[80]
|
Masse, I., Bordet, R., Deplanque, D., Al Khedr, A., Richard, F., et al. (2005) Lipid Lowering Agents Are Associated with a Slower cognitive Decline in Alzheimer’s Disease. Journal of Neurology, Neurosurgery & Psychiatry, 76, 1624-1629. http://dx.doi.org/10.1136/jnnp.2005.063388
|
[81]
|
Dimopoulos, N., Piperi, C., Salonicioti, A., Psarra, V., Mitsonis, C., Libersa, I., et al. (2007) Characterization of the Lipid Profile in Dementia and Depression in the Elderly. Journal of Geriatric Psychiatry and Neurology, 20, 138-144. http://dx.doi.org/10.1177/0891988707301867
|
[82]
|
Michikawa, M. (2003) Cholesterol Paradox: Is High Total or Low HDL Cholesterol Level a Risk for Alzheimer’s Disease? Journal of Neuroscience Research, 72, 141-146. http://dx.doi.org/10.1002/jnr.10585
|
[83]
|
Stefani, M. and Liguri, G. (2009) Cholesterol in Alzheimer’s Disease: Unresolved Questions. Current Alzheimer Research, 6, 15-29. http://dx.doi.org/10.2174/156720509787313899
|
[84]
|
Reitz, C. (2012) Dyslipidemia and Dementia: Current Epidemiology, Genetic Evidence, and Mechanisms behind the Associations. Journal of Alzheimer’s Disease, 30, S127-S145.
|
[85]
|
Anchisi, L., Dessi, S., Pani, A. and Mandas, A. (2012) Cholesterol Homeostasis: A Key to Prevent or Slow Down Neurodegeneration. Frontiers in Physiology, 3, 486-505.
|
[86]
|
Tan, Z.S., Seshadri, S., Beiser, A., Wilson, P.W., Kiel, D.P., Tocco, M., et al. (2003) Plasma Total Cholesterol Level as Risk Factor for Alzheimer Disease: The Framingham Study. Archives of Internal Medicine, 163, 1053-1057. http://dx.doi.org/10.1001/archinte.163.9.1053
|
[87]
|
Kálman, J. and Janka, Z. (2005) Cholesterol and Alzheimer’s Disease. Orvosi Hetilap, 146, 1903-1911.
|
[88]
|
Prasanthi, J., Schommer, E., Thomasson, S., Thompson, A., Feist, G. and Ghribi, O. (2008) Regulation of Beta-Amyloid Levels in the Brain of Cholesterol-Fed Rabbit, a Model System for Sporadic Alzheimer’s Disease. Mechanisms of Ageing and Development, 129, 649-655. http://dx.doi.org/10.1016/j.mad.2008.09.002
|
[89]
|
Ledesma, M.D. and Dotti, C.G. (2005) The Conflicting Role of Brain Cholesterol in Alzheimer’s Disease: Lessons from the Brain Plasminogen System. Biochemical Society Symposium, 72, 129-138. http://dx.doi.org/10.1042/bss0720129
|
[90]
|
Sjogren, M., Mielke, M., Gustafson, D., Zandi, P. and Skoog, I. (2006) Cholesterol and Alzheimer’s Disease—Is There a Relation?. Mechanisms of Ageing and Development, 127, 138-147. http://dx.doi.org/10.1016/j.mad.2005.09.020
|
[91]
|
Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A. and Breteler, M.M. (1999) Diabetes Mellitus and the Risk of Dementia: The Rotterdam Study. Neurology, 53, 1937-1942. http://dx.doi.org/10.1212/WNL.53.9.1937
|
[92]
|
Peila, R., Rodriguez, B.L. and Launer, L. (2002) Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies: The Honolulu-Asia Aging Study. Diabetes, 51, 1256-1262. http://dx.doi.org/10.2337/diabetes.51.4.1256
|
[93]
|
Grossman, H. (2003) Does Diabetes Protect or Provoke Alzheimer’s Disease? Insights into the Pathobiology and Future Treatment of Alzheimer’s Disease. CNS Spectrums, 8, 815-823.
|
[94]
|
Ho, L., Qin, L.W., Pompl, P.N., Xiang, Z., Wang, J., Zhao, Z., et al. (2004) Diet-Induced Insulin Resistance Promotes Amyloidosis in a Transgenic Mouse Model of Alzheimer’s Disease. The Federation of American Societies for Experimental Biology Journal, 18, 902-904. http://dx.doi.org/10.1096/fj.03-0978fje
|
[95]
|
Biessels, G.J. and Kappelle, L.J. (2005) Utrecht Diabetic Encephalopathy Study Group. Increased Risk of Alzheimer’s Disease in Type II Diabetes: Insulin Resistance of the Brain or Insulin-Induce Amyloid Pathology? Biochemical Society Transactions, 33, 1041-1044. http://dx.doi.org/10.1042/BST0331041
|
[96]
|
Whitmer, R.A. (2007) Type 2 Diabetes and Risk of Cognitive Impairment and Dementia. Current Neurology and Neuroscience Reports, 7, 373-380. http://dx.doi.org/10.1007/s11910-007-0058-7
|
[97]
|
Roriz-Fiho, J., SA-Roriz, T.M., Rosset, I., Camozzato, A.L., Santos, A.C., Chaves, M.L., et al. (2009) (Pre)Diabetes, Brain Aging, and Cognition. Biochimica et Biophysica Acta, 1792, 432-443. http://dx.doi.org/10.1016/j.bbadis.2008.12.003
|
[98]
|
Irie, F., Fitzpatrick, A.L., Lopez, O.L., Kuller, L.H., Peila, R., Newman, A.B., et al. (2008) Enhanced Risk for Alzheimer’s Disease in Persons with Type 2 Diabetes and APOE Epsilon4. The Cardiovascular Health Study Cognition Study. Archives of Neurology, 65, 89-93. http://dx.doi.org/10.1001/archneurol.2007.29
|
[99]
|
Akter, K., Lanza, E.A., Martin, S.A., Myronyuk, N., Rua, M. and Raffa, R.B. (2011) Diabetes Mellitus and Alzheimer’s Disease: Shared Pathology and Treatment? British Journal of Pharmacology, 71, 365-376. http://dx.doi.org/10.1111/j.1365-2125.2010.03830.x
|
[100]
|
Janson, J., Laedtke, T., Parisi, J.E., O’Brien, P., Petersen, R.C. and Butler, P.C. (2004) Increased Risk of Type 2 Diabetes in Alzheimer Disease. Diabetes, 53, 474-481. http://dx.doi.org/10.2337/diabetes.53.2.474
|
[101]
|
Beeler, N., Riederer, B.M., Waeber, G. and Abderrahmani, A. (2009) Role of the JNK-Interacting Protein 1/Islet Brain 1 in Cell Degeneration in Alzheimer Disease and Diabetes. Brain Research Bulletin, 80, 274-281. http://dx.doi.org/10.1016/j.brainresbull.2009.07.006
|
[102]
|
Abbadini, M., Zhu, G.J., Maggi, A., Pangrazzi, J., Donati, M.B. and Mussoni, L. (1987) Dermatan Sulphate Induces Plasminogen Activator Release in Perfused Rat Hindquarters. Blood, 70, 1858-1860.
|
[103]
|
Mannarino, E., Pascualini, L., Ciuffetti, G. and Lombardini, R. (1992) Effect of Oral Administration of Sulodexide on Fibrinolysis and Plasma Viscosity: A Pilot Study. Drug Investigation, 4, 346-350. http://dx.doi.org/10.1007/BF03259415
|
[104]
|
Mauro, M., Palmieri, G.C., Palazzini, E., Barbanti, M., Calanni, F. and Milani, M.R. (1993) Pharmacodynamic Effects of Single and Repeated Doses of Oral Sulodexide in Healthy Volunteers. A Placebo-Controlled Study with an Enteric-Coated Formulation. Current Medical Research and Opinion, 13, 87-95. http://dx.doi.org/10.1185/03007999309111537
|
[105]
|
Harenberg, J., Jeschek, M., Acker, M., Malsch, R., Huhle, G. and Heene, D.L. (1996) Effects of Low-Molecular Weight Dermatan Sulphate on Coagulation, Fibrinolysis and Tissue Factor Pathway Inhibitor in Healthy Volunteers. Blood Coagulation & Fibrinolysis, 7, 49-56. http://dx.doi.org/10.1097/00001721-199601000-00006
|
[106]
|
Colucci, M., Sardella, L., Barbanti, M., Calanni, F. and Semerano, N. (1997) Thrombolysis Enhancing Activity of a Low Molecular Weight Dermatan Sulphate (Desman 370) in Experimental Pulmonary Embolism in Rats. Thrombosis Research, 87, 441-446. http://dx.doi.org/10.1016/S0049-3848(97)00160-6
|
[107]
|
Castanon, M.M., Gamba, C. and Kordich, L.C. (2007) Insight into the Profibrinolytic Activity of Dermatan Sulfate: Effects on the Activation of Plasminogen Mediated by Tissue and Urinary Plasminogen Activators. Thrombosis Research, 120, 745-752. http://dx.doi.org/10.1016/j.thromres.2006.12.014
|
[108]
|
Busutti, L. and Breccia, A. (1991) Pharmacokinetics of Sulodexide after Single Oral Administration in Man. European Journal of Medical Research, 1, 25-36.
|
[109]
|
Crepaldi, G., Rossi, A., Coscetti, G., Abbruzzese, E., Calveri, U. and Calabro, A. (1992) Sulodexide Oral Administration Influences Blood Viscosity and Fibrinolysis. Drugs under Experimental and Clinical Research, 18, 189-195.
|
[110]
|
Ceriello, A., Quatraro, A., Marchi, E., Barbanti, M. and Giugliano, D. (1993) Impaired Fibrinolytic Response to Increased Thrombin Activation in Type 1 Diabetes Mellitus: Effects of the Glycosaminoglycan Sulodexide. Diabetes & Metabolism, 19, 225-229.
|
[111]
|
Jaques, L.B., Hiebert, L.M. and Wice, S.M. (1990) Endothelium as the Major Determinant in the Pharmacodynamic of Heparin and Dextran Sulphate. European Journal of Pharmacology, 183, 369-370. http://dx.doi.org/10.1016/0014-2999(90)93243-J
|
[112]
|
Milani, M.R., Busutti, L. and Breccia, A. (1992) Pharmacokinetics of Sulodexide Evaluated from 131I-Labelled Fast-Moving Heparin after Single Intravenous and Oral Administration on Man at Different Doses. British Journal of Clinical Research, 3, 161-178.
|
[113]
|
Silvestro, L., Lanzarotti, E., Marchi, E., Gori, M., Pescador, R., Ferro, L., et al. (1994) Human Pharmacokinetics of Glycosaminoglicans Using Deuterium-Labelled and Unlabeled Substances: Evidence for Oral Absorption. Seminars in Thrombosis and Hemostasis, 20, 281-292. http://dx.doi.org/10.1055/s-2007-1001914
|
[114]
|
Leveugle, B., Ding, W., Laurence, F., Dehouck, M.P., Scanameo, A., Cecchellli, R., et al. (1998) Heparin Oligosaccharides That Pass the Blood-Brain Barrier Inhibit Beta-Amyloid Precursor Protein Secretion and Heparin Binding to β-Amyloid Peptide. Journal of Neurochemistry, 70, 736-744. http://dx.doi.org/10.1046/j.1471-4159.1998.70020736.x
|
[115]
|
Ma, Q., Dudas, B., Hejna, M., Cornelli, U., Lee, J.M., Lorens, S., et al. (2002) The Blood-Brain Barrier Accessibility of a Heparin-Derived Oligosaccharides C3. Thrombosis Research, 105, 447-453. http://dx.doi.org/10.1016/S0049-3848(02)00050-6
|
[116]
|
Plow, E.F., Herren, T., Redlitz, A., Miles, L.A. and Hover-Plow, J.L. (1995) The Cell Biology of the Plasminogen System. FASEB Journal, 9, 838-845.
|
[117]
|
Collen, D. (1999) The Plasminogen (Fibrinolytic) System. Thrombosis and Haemostasis, 82, 259-270.
|
[118]
|
Hino, H., Akiyama, H., Iseki, E., Kato, M., Kondo, H., Ikeda, K., et al. (2001) Immunohistochemical Localization of Plasminogen Activator Inhibitor-1 in Rat and Human Brain Tissues. Neuroscience Letters, 297, 105-108. http://dx.doi.org/10.1016/S0304-3940(00)01679-7
|
[119]
|
Cacquevel, M., Launay, S., Castel, H., Benchenane, K., Chéenne, S., Bu’ee, L., et al. (2007) Ageing and Amyloid-Beta Peptide Deposition Contribute to an Impaired Brain Tissue Plasminogen Activator Activity by Different Mechanisms. Neurobiology of Disease, 27, 164-173. http://dx.doi.org/10.1016/j.nbd.2007.04.004
|
[120]
|
Periz, G. and Fortini, M.E. (2000) Proteolysis in Alzheimer’s Disease: Can Plasmin Tip the Balance? The European Molecular Biology Organization Reports, 1, 477-478.
|
[121]
|
Selkoe, D.J. (2001) Clearing the Brain’s Amyloid Cobwebs. Neuron, 32, 177-180. http://dx.doi.org/10.1016/S0896-6273(01)00475-5
|
[122]
|
Teesalu, T., Kulla, A., Simisker, A., Sirén, V., Lawrence, D.A., Asser, T., et al. (2004) Tissue Plasminogen Activator and Neuroserpin Are Widely Expressed in the Human Central Nervous System. Thrombosis and Haemostasis, 92, 358-368. http://dx.doi.org/10.1160/th02-12-0310
|
[123]
|
Aoyagi, T., Wada, T., Kojima, F., Nagai, M. and Takeuchi, T. (1994) Age-Dependent Decreases in Fibrinolytic Enzyme Activities in Serum of Healthy Subjects. Biological and Pharmaceutical Bulletin, 17, 348-351. http://dx.doi.org/10.1248/bpb.17.348
|
[124]
|
Aoyagi, T., Wada, T., Kojima, F., Harada, S., Takeuchi, T., Isse, K., et al. (1992) Deficiency of Fibrinolytic Enzyme Activities in the Serum of Patients with Alzheimer-Type Dementia. Experientia, 48, 656-659. http://dx.doi.org/10.1007/BF02118312
|
[125]
|
Tanzi, R.E., Moir, R.D. and Wagner, S.L. (2004) Clearance of Alzheimer’s Aβ Peptide. The Many Roads to Perdition. Neuron, 43, 605-608.
|
[126]
|
Zlokovic, B.V. (2004) Clearing Amyloid through the Blood-Brain Barrier. Journal of Neurochemistry, 89, 807-811. http://dx.doi.org/10.1111/j.1471-4159.2004.02385.x
|
[127]
|
Lasierra, J., Aza, M.J., Collado, P.S., Gonzalez, J. and Esteller, A. (1989) Inhibition of Fibrinolysis by Cellular Glutathione Depletion in the Rabbit. Thrombosis Research, 5, 347-355. http://dx.doi.org/10.1016/0049-3848(89)90313-7
|
[128]
|
Ledesma, M.D., Da Silva, J.S., Crassaerts, K., Delacourte, A., De Strooper, B. and Dotti, C.G. (2000) Brain Plasmin Enhances APP Alpha-Cleavage and Abeta Degradation and Is Reduced in Alzheiemer’s Disease Brains. The European Molecular Biology Organization Reports, 1, 530-535.
|
[129]
|
Yasojima, K., Akiyama, H., Mcgeer, E.G. and Mcgeer, P.L. (2001) Reduced Neprilysin in High Plaque Areas of Alzheimer Brain: A Possible Relationship to Deficient Degradation of Beta-Amyloid peptide. Neuroscience Letters, 297, 97-100. http://dx.doi.org/10.1016/S0304-3940(00)01675-X
|
[130]
|
Saito, T., Takaki, Y., Iwata, N., Trojanowski, J. and Saido, T.C. (2003) Alzheimer’s Disease, Neuropeptides, Neuropeptidase, and Amyloid-β Peptide. Science of Aging Knowledge Environment, 2003, pe1. http://dx.doi.org/10.1126/sageke.2003.3.pe1
|
[131]
|
Wang, D.S., Iwata, N., Hama, E., Saido, T.C. and Dickson, D.W. (2003) Oxidized Neprilysin in Aging and Alzheimer’s Disease Brains. Biochemical and Biophysical Research Communications, 310, 236-241. http://dx.doi.org/10.1016/j.bbrc.2003.09.003
|
[132]
|
Ledesma, M.D., Abad-Rodriguez, J., Galvan, C., Biondi, E., Navarro, P., Delacourte, A., et al. (2003) Raft Disorganization Leads to Reduced Plasmin Activity in Alzheimer’s Disease Brains. The European Molecular Biology Organization Reports, 4, 1190-1196. http://dx.doi.org/10.1038/sj.embor.7400021
|
[133]
|
Wang, D.S., Lipton, R.B., Katz, M.J., Davies, P., Buschke, H., Kuslansky, G., et al. (2005) Decrease Neprilysin Immunoreactivity in Alzheimer Disease, but Not in Pathological Aging. Journal of Neuropathology & Experimental Neurology, 64, 378-385. http://dx.doi.org/10.1093/jnen/64.5.378
|
[134]
|
Russo, R., Borghi, R., Markesbery, W., Tabaton, M. and Piccini, A. (2005) Neprylisin Decreases Uniformly in Alzheimer’s Disease and in Normal Aging. Federation of European Biochemical Societies Letters, 579, 6027-6030. http://dx.doi.org/10.1016/j.febslet.2005.09.054
|
[135]
|
Miners, J.S., Baig, S., Palmer, J., Palmer, L.E., Kehoe, P.G. and Love, S. (2008) Aβ-Degrading Enzymes in Alzheimer’s Disease. Brain Pathology, 18, 240-252. http://dx.doi.org/10.1111/j.1750-3639.2008.00132.x
|
[136]
|
Hellstrom-Lindahl, E., Ravid, R. and Nordberg, A. (2008) Age Dependent Decline of Neprilysin in Alzheimer’s Disease and Normal Brain: Inverse Correlation with A Beta Levels. Neurobiology of Aging, 29, 210-221. http://dx.doi.org/10.1016/j.neurobiolaging.2006.10.010
|
[137]
|
Vaughan, D.E., De Taeye, B.M. and Eren, M. (2007) PAI-1 Antagonists: Predictable Indications and Unconventional Applications. Current Drug Targets, 8, 962-970. http://dx.doi.org/10.2174/138945007781662364
|
[138]
|
Eren, M., Gleaves, L.A., Atkinson, J.B., Le, R., Declerck, P.J. and Vaughan, D.E. (2007) Reactive Site-Dependent Phenotypic Alterations in Plasminogen Activactor Inhibitor-1 Transgenic Mice. Journal of Thrombosis and Haemostasist, 5, 1500-1508. http://dx.doi.org/10.1111/j.1538-7836.2007.02587.x
|
[139]
|
Akhter, H., Katre, A., Li, L., Liu, X. and Liu, R.M. (2011) Therapeutic Potential and Anti-Amyloidosis Mechanisms of Tert-Butylhydroquinone for Alzheimer’s Disease. Journal of Alzheimer’s Disease, 26, 767-778.
|
[140]
|
Jones, D.P. (2002) Redox Potential of GSH/GSSG Couple: Assay and Biological Significance. Methods in Enzymology, 348, 93-112. http://dx.doi.org/10.1016/S0076-6879(02)48630-2
|
[141]
|
Bains, J.S. and Shaw, C.A. (1997) Neurodegenerative Disorders in Human: the Role of Glutathione in Oxidative Stress-Mediated Neuronal Death. Brain Research Reviews, 25, 335-358. http://dx.doi.org/10.1016/S0165-0173(97)00045-3
|
[142]
|
Lu, S.C. (1999) Regulation of Hepatic Glutathione Synthesis: Current Concepts and Controversies. The Federation of American Societies for Experimental Biology Journal, 13, 1169-1183.
|
[143]
|
Griffith, O.W. (1999) Biologic and Pharmacologic Regulation of Mammalian Glutathione Synthesis. Free Radical Biology & Medicine, 27, 922-935. http://dx.doi.org/10.1016/S0891-5849(99)00176-8
|
[144]
|
Aoyama, K., Suh, S.W., Hamby, A.M., Liu, J., Chan, W.Y., Chen, Y., et al. (2006) Neuronal Glutathione Deficiency and Age-Dependent Neurodegeneration in the EAAC1 Deficient Mouse. Nature Neuroscience, 9, 119-126. http://dx.doi.org/10.1038/nn1609
|
[145]
|
Byrd, A.S., Sikorska, M., Walker, P.R. and Sandhu, J.K. (2004) Effects of Glutathione Depletion on the Viability of Human NT2-Derived Neuronal and Astroglial Cultures. Neuron Glia Biology, 1, 317-328. http://dx.doi.org/10.1017/S1740925X05000207
|
[146]
|
Lee, M., Cho, T., Jantaratnotai, N., Wang, Y.T., McGeer, E. and McGeer, P.L. (2010) Depletion of GSH in Glial Cells Induces Neurotoxicity: Relevance to Aging and Degenerative Neurological Diseases. The Federation of American Societies for Experimental Biology Journal, 24, 2533-2545. http://dx.doi.org/10.1096/fj.09-149997
|
[147]
|
Barker, J.E., Heales, S.J., Cassidy, A., Bolanos, J.P., Land, J.M. and Clark, J.B. (1996) Depletion of Brain Glutathione Results in a Decrease of Glutathione Reductase Activity; An Enzyme Susceptible to Oxidative Damage. Brain Research, 716, 118-122. http://dx.doi.org/10.1016/0006-8993(96)00003-0
|
[148]
|
Mizui, T., Kinouchi, H. and Chan, P.H. (1992) Depletion of Brain Glutathione by Buthionine Sulfoximine Enhances Cerebral ischemic Injury in Rats. American Journal of Physiology, 262, H313-H317.
|
[149]
|
Mytilineou, C., Leonardi, E.K., Radcliffe, P.H., Heinonen, E.H., Han, S.K., Werner, P., et al. (1998) Deprenyl and Desmethylselegiline Protect Mesencephalic Neurons from Toxicity Induced by Glutathione Depletion. Journal of Pharmacology and Experimental Therapeutics, 284, 700-706.
|
[150]
|
Li, Y., Maher, P. and Schubert, D. (1997) A Role for 12-Lipoxygenase in Nerve Cell Death Caused by Glutathione Depletion. Neuron, 19, 453-463. http://dx.doi.org/10.1016/S0896-6273(00)80953-8
|
[151]
|
Sandhu, J.K., Gardaneh, M., Iwasiow, R., Lanthier, P., Gangaraju, S., Ribbeco-Lutkiewicz, M., et al. (2009) Astrocyte-Secreted GDNF and Glutathione Antioxidant System Project Neurons against 6OHDA Cytotoxicity. Neurobiology of Disease, 33, 405-414. http://dx.doi.org/10.1016/j.nbd.2008.11.016
|
[152]
|
Liu, R. and Choi, J. (2000) Age-Associated Decline in Gamma-Glutamylcysteine Sinthetase Gene Expression in Rats. Free Radical Biology & Medicine, 28, 566-574. http://dx.doi.org/10.1016/S0891-5849(99)00269-5
|
[153]
|
Liu, H., Wang, H., Shenvi, S., Hagen, T.M. and Liu, R.M. (2004) Glutathione Metabolism during Aging and in Alzheimer Disease. Annals of the New York Academy of Sciences, 1019, 346-349. http://dx.doi.org/10.1196/annals.1297.059
|
[154]
|
Tchaikovskaya, T., Fraifeld, V., Urphanishvili, T., Andorfe, J.H., Davies, P. and Listowsky, I. (2005) Glutathione S-Transferase hGSTM3 and Ageing-Associated Neurodegeneration: Relationship to Alzheimer’s Disease. Mechanisms of Ageing and Development, 126, 309-315. http://dx.doi.org/10.1016/j.mad.2004.08.029
|
[155]
|
Zhu, Y., Carvey, P.M. and Ling, Z. (2006) Age-Related Changes in Glutathione and Glutathione-Related Enzymes in Rat Brain. Brain Research, 1090, 35-44. http://dx.doi.org/10.1016/j.brainres.2006.03.063
|
[156]
|
Butterfield, D.A., Perluig, M. and Sultana, R. (2006) Oxidative Stress in Alzheimer’s Disease Brain: New Insights from Redox Proteomics. European Journal of Pharmacology, 545, 39-50. http://dx.doi.org/10.1016/j.ejphar.2006.06.026
|
[157]
|
Sian, J., Dexter, D.T., Lees, A.J., Daniel, S., Agid, Y., Javoy-Agid, F., et al. (1994) Alterations in Glutathione Level in Parkinson’s Disease and Other Neurodegeneratives Disorders Affecting Basal Ganglia. Annals of Neurology, 36, 348-355. http://dx.doi.org/10.1002/ana.410360305
|
[158]
|
Good, P.F., Werner, P., Hsu, A., Olanow, C.W. and Perl, D.P. (1996) Evidence of Neuronal Oxidative Damage in Alzheimer’s Disease. American Journal of Pathology, 149, 21-28.
|
[159]
|
Townsend, D.M., Tew, K.D. and Tapiero, H. (2003) The Importance of Glutathione in Human Disease. Biomedicine & Pharmacotherapy, 57, 145-55. http://dx.doi.org/10.1016/S0753-3322(03)00043-X
|
[160]
|
Yoshida, K., Hirokawa, J., Tagami, S., Kawakami, Y., Urata, Y. and Kondo, T. (1995) Weakened Cellular Scavenging Activity against Oxidative Stress in Diabetes Mellitus: Regulation of Glutathione Synthesis and Efflux. Diabetologia, 38, 201-210. http://dx.doi.org/10.1007/BF00400095
|
[161]
|
Regan, R.F. and Guo, Y. (1999) Extracellular Reduced Glutathione Increases Neuronal Vulnerability to Combined Chemical Hypoxia and Glucose Deprivation. Brain Research, 817, 145-150. http://dx.doi.org/10.1016/S0006-8993(98)01252-9
|
[162]
|
Sharma, A., Kharb, S., Chugh, S.N., Kakkar, R. and Singh, G.P. (2000) Effect of Glycemic Control and Vitamin E Supplementation on Total Glutathione Content in Non-Insulin-Dependent Diabetes Mellitus. Annals of Nutrition and Metabolism, 44, 11-13. http://dx.doi.org/10.1159/000012815
|
[163]
|
Giral, P., Jacob, N., Dourmap, C., Carrié, A., Bruckert, E., Girerd, X., et al. (2008) Elevated Gammaglutamyltransferase Activity and Perturbed Thiol Profile Are Associated with Features of Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 587-593. http://dx.doi.org/10.1161/ATVBAHA.107.157891
|
[164]
|
Ballatori, N., Krance, S.M., Notenboom, S., Shi, S., Tieu, K. and Hammond, C.L. (2009) Glutathione Dysregulation and the Etiology and Progression of Human Diseases. Biological Chemistry, 390, 191-214. http://dx.doi.org/10.1515/BC.2009.033
|
[165]
|
Samiec, P.S., Drews-Botsch, C., Flagg, E.W., Kurtz, J.C., Sternberg, P., Reed, R.L., et al. (1998) Glutathione in Human Plasma: Decline in Association with Aging, Age-Related Macular Degeneration, and Diabetes. Free Radical Biology & Medicine, 24, 699-704. http://dx.doi.org/10.1016/S0891-5849(97)00286-4
|
[166]
|
Lasierra-Cirujeda, J., Aza, M.J., Lasierra-Ibanez, A. and Aza, M.M. (1991) AGING: Thromboembolic Disease, Metabolic Syndrome, Type 2 Diabetes Mellitus, and Alzheimer Disease. In Publication Phase.
|
[167]
|
Vague, P., Raccah, D. and Scelles, V. (1995) Hypofibrinolysis and the Insulin Resistance Syndrome. International Journal of Obesity and Related Metabolic Disorders, 19, S11-S15.
|
[168]
|
Juhan-Vague, I., Alessi, M.C. and Vague, P. (1996) Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in Non-Insulin-Dependent Diabetes Mellitus. Annals of Medicine, 28, 371-380. http://dx.doi.org/10.3109/07853899608999095
|
[169]
|
Juhan-Vague, I. and Alessi, M.C. (1997) PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events. Thrombosis and Haemostasis, 78, 656-660.
|
[170]
|
Juhan-Vague, I., Alessi, M.C. and Morange, P.E. (2000) Hypofibrinolysis and Increased PAI-1 Are Linked to Atherothrombosis via Insulin Resistance and Obesity. Annals of Medicine, 32, 78-84.
|
[171]
|
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., et al. (2003) Insulin-Degrading Enzyme Regulates the Levels of Insulin, Amyloid Beta-Protein, and the Beta-Amyloid Precursor Protein Intracellular Domain in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 100, 4162-4167. http://dx.doi.org/10.1073/pnas.0230450100
|
[172]
|
Juhan-Vague, I., Alessi, M.C., Mavri, A. and Morange, P.E. (2003) Plasminogen Activator Inhibitor-1 Inflammation, Obesity, Insulin Resistance and Vascular Risk. Journal of Thrombosis and Haemostasis, 1, 1575-1579. http://dx.doi.org/10.1046/j.1538-7836.2003.00279.x
|
[173]
|
Skurk, T. and Hauner, H. (2004) Obesity and Impaired Fibrinolysis: Role of Adipose Production of Plasminogen Activator Inhibitor-1. International Journal of Obesity and Related Metabolic Disorders, 28, 1357-1364. http://dx.doi.org/10.1038/sj.ijo.0802778
|
[174]
|
Mavri, A., Alessi, M.C. and Juhan-Vague, I. (2004) Hypofibrinolysis in the Insulin Resistance Syndrome: Implication in Cardiovascular Diseases. Journal of Internal Medicine, 255, 448-456. http://dx.doi.org/10.1046/j.1365-2796.2003.01288.x
|
[175]
|
Alessi, M.C. and Juhan-Vague, I. (2006) PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2200-2207. http://dx.doi.org/10.1161/01.ATV.0000242905.41404.68
|
[176]
|
Dimova, E.Y., Samoylenko, A. and Kietzmann, T. (2004) Oxidative Stress and Hypoxia: Implications for Plasminogen Activator Inhibitor-1 Expression. Antioxidants & Redox Signaling, 6, 777-791. http://dx.doi.org/10.1089/1523086041361596
|
[177]
|
Vayalil, P.K., Olman, M., Murphy-Ullrich, J.E., Postlethwait, E.M. and Liu, R.M. (2005) Glutathione Restores Collagen Degradation in TGF-β-Treated Fibroblasts by Blocking Plasminogen Activator Inhibitor-1 Expression and Activating Palsminogen. American Journal of Physiology. Lung Cellular and Molecular Physiology, 289, L937-l945. http://dx.doi.org/10.1152/ajplung.00150.2005
|
[178]
|
Kutz, S., Hordines, J., McKeown-Longo, P.J. and Higgins, P.J. (2001) TGF-β1-Induced PAI-1 Gene Expression Requires MEK Activity and Cell-to-Substrate Adhesion. Journal of Cell Science, 114, 3905-3914.
|
[179]
|
Kutz, S.M., Higging, C.E., Samarakoon, K., Higging, S.P., Allen, R.R., Qi, L., et al. (2006) TGF-Beta 1-Induced PAI-1 Expression Is Ebox/USF-Dependent and Requires EGFR Signal in. Experimental Cell Research, 312, 1093- 1105. http://dx.doi.org/10.1016/j.yexcr.2005.12.027
|
[180]
|
Fain, J.N., Tichansky, D.S. and Madan, A.K. (2005) Transforming Growth Factor Beta 1 Release by Human Adipose Tissue Enhanced Obesity. Metabolism, 54, 1546-1551. http://dx.doi.org/10.1016/j.metabol.2005.05.024
|
[181]
|
Herder, C., Zierer, A., Koenig, W., Roden, M., Meisinger, C. and Thorand, B. (2009) Transforming Growth Factor-β1 and Incident Type 2 Diabetes: Results from the MONICA/KORA Case-Cohort Study, 1984-2002. Diabetes Care, 32, 1921-1923. http://dx.doi.org/10.2337/dc09-0476
|
[182]
|
Kutz, S.M., Higgins, C.E. and Higgins, P.J. (2012) Novel Combinatorial Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer’s Disease. Molecular Medicine & Therapeutics, 1, 2. http://dx.doi.org/10.4172/2324-8769.1000106
|
[183]
|
Higgins, P.J. (2006) The TGF-β1/Upstream Stimulatory Factor-Regulated PAI-1 Gene: Potential Involvement and a Therapeutic Target in Alzheimer’s Disease. Journal of Biomedicine and Biotechnology, 2006, Article ID: 15792. http://dx.doi.org/10.1155/jbb/2006/15792
|
[184]
|
Martina, V., Bruno, G.A., Pannocchia, A., Zumpano, E., Tagliabue, M. and Trucco, A., et al. (1996) PAI-1 Reduction after Treatment with Glutathione in NIDDM. Fibrinolysis, 10, 63-65. http://dx.doi.org/10.1016/S0268-9499(96)80052-X
|
[185]
|
Martina, V., Bruno, G.A., Zumpano, E., Origlia, C., Quaranta, L. and Pescarmona, G.P. (2001) Administration of Glutathione in Patients with Type 2 Diabetes Mellitus Increases the Platelet Constitutive Nitric Oxide Synthase Activity and Reduces PAI-1. Journal of Endocrinological Investigation, 24, 37-41. http://dx.doi.org/10.1007/BF03343806
|
[186]
|
Perego, M., Palmieri, G. and Nazzari, M. (1982) Effects of Oral and Parenteral 3-GS Administration on Blood Lipids and Haemostatic Parameters in Atherosclerotic Hyperlipaemic Patients. In: Lenzi, S. and Descovich, C.G., Eds., Atherosclerosis: Etiopathogenesis, Clinical Evaluation and Therapy, Editrice Compositori, Bologna, 157-163.
|
[187]
|
Bonacci, C., Crolle, G., Olivi, A., Romagnoli, G., Marchetto, N., et al. (1986) Effetti del sulodexide in pazienti anziani con vasculopatia arteriosclerotica cerebrale [Effects of Sulodexide in Elderly Patients with Artherosclerotic Cerebral Vascular Disease]. Acta gerontologica, 36, 228-235.
|
[188]
|
Capone-Braga, M., Tellini, L., Boncompagni, L., Bettoni, M., Burali, A. and Bensi, A. (1987) Approccio terapeutico con sulodexide in pazienti con vasculopatia aterosclerotica a varia localizzazione [Sulodexide Treatment Approach in Patients with Atherosclerotic Vascular Disease with Various Localizations]. Clinical Therapeutics, 120, 25-31.
|
[189]
|
Cospite, M., Milio, G., Ferrara, F., et al. (1985) Double-Blind Study of the Pharmacological Effect of Sulodexide in Patients with Multiple Atherosclerotic Vascular Disease. European Review for Medical and Pharmacological Sciences, 7, 97-106.
|
[190]
|
Bonanno, G., Bonaccorso, R., Dell’Ali, C. and Salanitri, G. (1985) Sulodexide in the Treatment of Atherosclerosis: A Controlled Clinical Trial. Acta Therapeutica, 11, 87-98.
|
[191]
|
Postiglione, F., Pisani, P., Gisonni, P., Perrota, P., Gisonni, M., et al. (1986) Sulodexide in the Therapy of Vasculopathies. Clinical Therapeutics, 117, 223-231.
|
[192]
|
Santus, G., Sottini, G., Lombardi, G., Rozzini, R. and Inzoli, R. (1984) L’uso del sulodexide nei vasculopatici cerebrali con dislipidemia e/o diabete: Contributo clinico statistico. In: Lenci, S. and Descovich, G.C., Eds., Atherosclerosis and Cardiovascular Diseases, Editrice Compositori, Bologna, 415-420.
|
[193]
|
Parnetti, L., Mari, D., Abate, G., Balestreri, R., Cucinotta, D., Coppola, R., et al. (1997) Vascular Dementia Italian Sulodexide Study (VA.D.I.S.S.). Clinical and Biological Results. Thrombosis Research, 87, 225-233. http://dx.doi.org/10.1016/S0049-3848(97)00122-9
|
[194]
|
Rodriguez-Martinez, M.A. and Ruiz-Torres, A. (1992) Homeostasis between Lipid Peroxidation and Antioxidant Enzyme Activities in Healthy Human Aging. Mechanisms of Ageing and Development, 66, 213-222. http://dx.doi.org/10.1016/0047-6374(92)90137-3
|
[195]
|
Klapcinska, B., Derejczyk, J., Wieczorowska-Tobis, K., Sobezak, A., Sadowska-Krepa, E., et al. (2000) Antioxidant Defense in Centenarians (a Preliminary Study). Acta Biochimica Polonica, 47, 281-292.
|
[196]
|
Mari, D., Mannucci, P., Coppola, R., Bottassao, B., Bauer, K.A. and Rosenberg, R.D. (1995) Hypercoagulability in Centenarians: The Paradox of Successful Aging. Blood, 85, 3144-3149.
|
[197]
|
Mari, D., Oglian, G., Casataldi, D., Vitale, G., Bollini, E.M. and Lio, D. (2008) Hemotasis and Ageing. Immunity & Ageing, 5, 12. http://dx.doi.org/10.1186/1742-4933-5-12
|